Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD
– Phase 3 MARCH study meets primary endpoint and demonstrates statistical significance across key endpoints in all PFIC types. Receives Best of Liver Meeting distinction. – RISE study in infants with ALGS shows safety and tolerability of LIVMARLI for ages ≥2 months. – Real-world evidence highlights LIVMARLI’s safety and tolerability in patients with ALGS. – … [Read more…]